Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Probable inactive 1-aminocyclopropane-1-carboxylate synthase-like protein 2 (ACCSL) is a homolog of the enzyme 1-aminocyclopropane-1-carboxylate synthase, which in plants catalyzes the conversion of S-adenosylmethionine to the ethylene precursor ACC via a lyase reaction. However, ACCSL itself is designated as "probable inactive" based on sequence or functional annotation, meaning it lacks catalytic activity and does not perform the biochemical role associated with its active counterparts. In humans and most non-plant systems, this homolog is not implicated in any physiological process, disease, or therapeutic target class. It may be an evolutionary remnant or pseudogene product identified by sequence similarity rather than function, and as such, has no established biological or pharmacological role[3][5][6][7].
None applicable (not an active target; homologous enzymes in other species act as lyases but this protein is likely inactive)[3][5][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable inactive 1-aminocyclopropane-1-carboxylate synthase-like protein 2 (ACCSL).